Thesis Approved by:

[Signatures]

Major Advisor

Dean
Erbb2: A Regulator of the Skin’s Response to Ultraviolet Radiation

By

Rebecca Jangraw Ophardt

A THESIS

Submitted to the faculty of the Graduate School of the Creighton University in Partial Fulfillment of the Requirements for the degree of Master of Science in the Department of Biomedical Sciences

Omaha, NE

May 20, 2008
Abstract

Non-melanoma skin cancer is the most commonly diagnosed cancer in the United States. The cause of most non-melanoma skin cancer is prolonged exposure to UV-irradiation. UV-irradiation acts as both an initiator and tumor promoter, possibly through its activation of receptor tyrosine kinases (RTKs) such as the members of the Erbb family. Erbb2, an orphan receptor and member of the Erbb family, was recently demonstrated to be involved in the regulation of cell cycle progression after UV-induced DNA damage. This report describes the use of a skin-targeted conditional Erbb2 null mouse (to be referred here as an Erbb2 mutant mouse) to study Erbb2’s role in the skin’s response to UV-irradiation. Using this model, the effects of Erbb2 on cell cycle progression, DNA damage repair, and mutagenesis were analyzed after UV-irradiation. Surprisingly, Erbb2 mutant skin lacks a UV-induced S-phase arrest observed in previous studies utilizing the Erbb2 inhibitor AG825, suggesting that Erbb2 mutant skin compensates for its loss of Erbb2. However, Erbb2 reduces the efficiency of DNA damage repair and increases clonal expansion of keratinocytes with Trp53 mutations through mechanisms independent of its regulation of the cell cycle after UV-irradiation. These results suggest that erbb2 may contribute to skin carcinogenesis through multiple mechanisms.
Dedication

This thesis is dedicated to my husband, Jon, whose unconditional love, patience, and support, even from a different state, were instrumental in helping me complete this work.

This thesis is also dedicated to my parents, who taught me that anything is possible and made me determined to achieve my goals. To my father, who has always challenged me to think and not always take the easy route. And, to my mother, my friend, who’s enduring patience, strength, and wisdom have been and continue to be invaluable to me.
Acknowledgements

My sincere thanks to my advisor, Dr. Laura Hansen, for her mentoring and guidance. Thank you for having confidence in me and for teaching me to think like a scientist. This thesis would also not have been possible without the members of the Hansen Lab, especially Jodi Nicolai, David Lynch, Kyle Bischel, Andrew Bowles, Jackie Evenson, Jodi Yanagida, Jennifer Correia, and Jessica Gaulter. I am grateful for their contributions to my research and this experience would not have been nearly as much fun without them. (Go Team Hansen!) Lastly, I extend my thanks to Dr. Greg Perry in the Flow Cytometry Core Facility, who was instrumental in collecting data from my samples and who provided wonderful troubleshooting advice.
Table of Contents

Abstract.............................................................................................................................................. iii

Dedication........................................................................................................................................ iv

Acknowledgements .................................................................................................................. v

Table of Contents ................................................................................................................ vi

List of Figures and Tables ....................................................................................................... viii

Figure Contributions ........................................................................................................ x

Abbreviations ........................................................................................................................ xi

Chapter 1: Introduction ........................................................................................................ 1

The skin is our barrier from the elements .................................................................................. 1

UV irradiation causes DNA damage, the repair of which is facilitated by cell cycle arrest. .............................................................................................................................. 2

Insufficient DNA damage repair results in mutagenesis, the most common of which is Trp53 mutation .............................................................................................................. 4

UV irradiation causes skin cancer ................................................................................................ 5

UV irradiation indirectly activates receptor tyrosine kinases, including Erbb family members ........................................................................................................................... 7

Erbb2 is a member of the Erbb family of RTKs ........................................................................ 8

Erbb2 regulates normal cellular processes ................................................................................. 10

Erbb2 is a therapeutic target in a number of cancers ............................................................... 11

Why study Erbb2’s role in skin cancer? .................................................................................. 12

Chapter 2: Materials and Methods ................................................................................... 15

Animals ........................................................................................................................................... 15
Chapter 3: Results........................................................................................................... 21

Skin-targeted *Erbb2* mutant mice were developed to overcome off-target effects of other models.................................................................................................................. 21

Genetic ablation of *Erbb2* results in small differences in cell cycle progression after UV-irradiation.................................................................................................................. 23

Genetic ablation of *Erbb2* improves DNA damage repair after UV-irradiation ........ 28

p53-positive foci are smaller in UV-irradiated skin from *Erbb2* mutant mice............. 30

*Erbb2* mutant mice may adapt to loss of Erbb2 by maintaining Cdc25A ................. 32

Chapter 4: Discussion..................................................................................................... 37

Bibliography .................................................................................................................... 45
List of Figures and Tables

Chapter 1: Introduction ................................................................................................... 1

Figure 1. ATR pathway activation results in cell cycle arrest through Cdc25A degradation........................................................................................................................... 4

Figure 2. The multistage tumorigenesis model............................................................. 6

Figure 3. UV regulation of Erbb phosphorylation and autocrine signaling............... 8

Table 1. Erbb family ligand specificity........................................................................ 10

Figure 4. Potential mechanism for Erbb2 regulation of the ATR DNA damage response pathway. .................................................................................................................. 13

Chapter 3: Results ........................................................................................................... 21

Figure 5. Generation of Erbb2 mutant mice. .............................................................. 22

Figure 6. Erbb2 immunoreactivity is decreased in Erbb2 mutant skin..................... 23

Figure 7. UV-induced activation of Erbb2. ................................................................ 24

Figure 8. Cell cycle progression from Erbb2 mutant and littermate controls after receiving 43 UV-exposures totaling 26 kJ/m^2. ................................................................. 25

Figure 9. DNA synthesis after UV-irradiation quantified by BrdU labeling index.... 27

Figure 10. Immunoblotting consistent with normal cell cycle progression............. 28

Figure 11. UV-induced DNA damage quantified by cyclobutane dimer immunofluorescence intensity. .................................................................................. 29

Figure 12. Mutagenesis quantified by p53 immunofluorescence. .............................. 31

Figure 13. Flow cytometry analysis of cultured keratinocytes from Erbb2 mutant mice and littermate controls.............................................................. 33
Figure 14. Cre recombinase infection of Erbb2<sup>fl/fl</sup> keratinocytes reduces Erbb2 immunoreactivity. ................................................................. 34

Figure 15. Flow cytometry analysis of virus-infected Erbb2<sup>fl/fl</sup> keratinocytes. ....... 34

Figure 16. Cdc25A immunoreactivity in Cre recombinase virus-infected Erbb2<sup>fl/fl</sup> and Erbb2 mutant keratinocytes. ............................................................................................................ 35

Figure 17. Cdc25A immunoreactivity in Erbb2 mutant keratinocytes..................... 36
## Figure Contributions

<table>
<thead>
<tr>
<th>Name</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jennifer Correia</td>
<td>p53 and BrdU-labeling index quantification (Figure 9B and Figure 12B and C)</td>
</tr>
<tr>
<td>Dr. Laura Hansen</td>
<td>Cyclobutane dimer quantification and photograph of Erbb2 mutant mouse (Figure 5C and Figure 11A)</td>
</tr>
<tr>
<td>David Lynch</td>
<td><em>In vitro</em> flow cytometry (Erbb2 mutant and control, Figure 13)</td>
</tr>
<tr>
<td>Justin Madson</td>
<td>Immunoblotting of phospho-Erb2 (mouse keratinocytes, Figure 7B, reprinted from Am J Pathol 2006;169:1402-1414 with permission from the American Society for Investigative Pathology)</td>
</tr>
<tr>
<td>Jodi Nicolai</td>
<td>Erbb2 immunoblotting and quantification in Erbb2 mutant skin and immunoblotting of phospho-Erb2 in UV-exposed human skin (Figure 5B and Figure 7A)</td>
</tr>
<tr>
<td>Jodi Yanagida</td>
<td>Photographs of BrdU immunofluorescence (Figure 9A)</td>
</tr>
</tbody>
</table>
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2MED</td>
<td>Twice the minimal erythema dose</td>
</tr>
<tr>
<td>ATR</td>
<td>Ataxia telangiectasia mutated and Rad3 related</td>
</tr>
<tr>
<td>a.u.</td>
<td>Arbitrary Unit</td>
</tr>
<tr>
<td>BCC</td>
<td>Basal Cell Carcinoma</td>
</tr>
<tr>
<td>BrdU</td>
<td>Bromodeoxyuridine</td>
</tr>
<tr>
<td>C</td>
<td>Cytosine</td>
</tr>
<tr>
<td>CBD</td>
<td>Cyclobutane dimers</td>
</tr>
<tr>
<td>CDK</td>
<td>Cyclin dependent kinase</td>
</tr>
<tr>
<td>DMBA</td>
<td>Di-methyl-benzanthracene</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal Growth Factor Receptor</td>
</tr>
<tr>
<td>G\textsubscript{o}/G\textsubscript{1}</td>
<td>Gap 0 / Gap 1 Phases</td>
</tr>
<tr>
<td>G\textsubscript{2}/M</td>
<td>Gap 2 / Mitosis Phases</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Glyceraldehyde 3-Phosphate Dehydrogenase</td>
</tr>
<tr>
<td>h</td>
<td>Hour(s)</td>
</tr>
<tr>
<td>HER2</td>
<td>Human EGF receptor 2</td>
</tr>
<tr>
<td>K14</td>
<td>Keratin 14</td>
</tr>
<tr>
<td>kDa</td>
<td>Kilodalton</td>
</tr>
<tr>
<td>min</td>
<td>Minute(s)</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PCNA</td>
<td>Proliferating cell nuclear antigen</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphatidylinositol 3-kinase</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>PLC</td>
<td>Phospholipase C</td>
</tr>
<tr>
<td>PTB</td>
<td>Phosphotyrosine binding</td>
</tr>
<tr>
<td>PTP</td>
<td>Protein tyrosine phosphatase</td>
</tr>
<tr>
<td>RTK</td>
<td>Receptor Tyrosine Kinase</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive Oxygen Species</td>
</tr>
<tr>
<td>SCC</td>
<td>Squamous Cell Carcinoma</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis</td>
</tr>
<tr>
<td>SH2</td>
<td>src homology-2</td>
</tr>
<tr>
<td>T</td>
<td>Thymine</td>
</tr>
<tr>
<td>TPA</td>
<td>12-O-tetradecanoylphorbol-13-acetate</td>
</tr>
<tr>
<td>UV</td>
<td>Ultraviolet</td>
</tr>
</tbody>
</table>

xii
Chapter 1: Introduction

The skin is our barrier from the elements

The skin is a complex organ containing several different layers, structures, and cell types. It protects the body from environmental insults, small molecules, and water loss. The skin is comprised of three layers; from the outer-most layer they are: the epidermis, the dermis, and the subcutaneous layer. The epidermis is mostly (>90%) keratinocytes with other cell types such as melanocytes (pigment cells), Langerhans cells (antigen-presenting cells), and Merkel cells (neuroendocrine cells, also found in the dermis). Interior to the epidermis is the basement membrane which separates the keratinocytes from the dermis. The dermis, which consists mostly of collagen and elastic fibrils and fibroblastic cells, contains structures such as hair follicles and sweat glands. The subcutaneous layer lies underneath the dermis, consists mainly of adipose tissue and connects the skin to underlying muscle and bone. Nerve fibers exist in all three skin layers with blood vessels present to provide nutrients and remove waste from the dermal and subcutaneous layers.

The keratinocytes in the epidermis form a keratinized stratified squamous epithelium. The layers of the stratified epithelium are, from the basement membrane, the stratum basale, stratum spinosum, stratum granulosum, stratum lucidum (sometimes present), and stratum corneum. The cells in the basal layer, or stratum basale, are columnar shaped keratinocytes that rapidly undergo asymmetric cell divisions and promote stratification and differentiation (1). Over time, these cells change in phenotype and protein expression profiles and migrate toward the skin’s surface. As this migration
occurs, the cells become more rounded and granular, then squamous, and are eventually shed or lost due to environmental stresses. The terminally differentiated cells of the stratum corneum are considered ‘dead cells’ as they are anucleate. They are replaced as additional cells migrate upwards. In this way, the skin maintains homeostasis.

**UV irradiation causes DNA damage, the repair of which is facilitated by cell cycle arrest**

As the interface with the outside world and barrier from the elements, the skin sustains damage from and responds to outside stimuli such as ultraviolet (UV) irradiation. UV makes up 10% of the total solar radiation that reaches the earth and can be divided into three categories, based on wavelength. These are, in order of increasing energy and decreasing penetration: UVA (320-400 nm), UVB (280-320 nm), and UVC (200-280 nm). UVC and part of UVB are filtered out by the atmosphere and therefore never reach the earth except in areas where the ozone is depleted. Therefore, the solar radiation that reaches the earth is mostly UVA (~90%) and some UVB (~10%).

UVA and UVB both cause DNA damage through different mechanisms. UVA penetrates into the epidermis and the top layers of the dermis causing DNA damage indirectly through the creation of reactive oxygen species (ROS). UVB causes damage directly in the epidermis through DNA absorption. UVB is considered to be more carcinogenic than UVA (2).

The major forms of UV-induced DNA damage caused by ROS or UVB absorption are DNA photoproducts (i.e. cyclobutane dimers and 6-4 photoproducts). DNA photoproducts are bulky adducts that result from bonds formed between adjacent pyrimidine bases. DNA photoproducts resulting from UV-irradiation are repaired through
nucleotide excision repair. In this process, DNA is repaired by several factors involved in (i) recognition of DNA damage, (ii) cleavage of the DNA several nucleotides of each side of the adduct, (iii) removal of the damaged oligomer, (iv) recruitment of polymerase machinery to fill in the gap, and (v) ligation (3).

One way that UV-induced DNA damage is recognized and nucleotide excision repair is facilitated is though the ataxia telangiectasia mutated and Rad3 related (ATR) pathway (Figure 1A, (4)). ATR is recruited to sites of DNA damage recognition proteins (5;6). ATR then phosphorylates the activating phosphorylation sites on the Chk1 kinase (5;7), which phosphorylates Cdc25A and targets it for ubiquitin-dependent degradation (8;9). The members of the Cdc25 family (Cdc25A, Cdc25B, and Cdc25C) are phosphatases responsible for dephosphorylating the inhibitory phosphorylation sites on cyclin dependent kinases 1 and 2 (CDK1, CDK2), resulting in their activation. The activation of CDK-cyclin complexes regulates progression through each phase of the cell cycle (Figure 1B). Cdc25A normally activates CDK2, allowing progression through the G1- and S-phase regulatory checkpoints (10), while Cdc25B/C are involved in the activation of the CDK1-cyclin B complex and the entry into mitosis (11-13). When Cdc25A is degraded in response to UV-induced DNA damage, cyclin/CDK2 complexes are inhibited and cells accumulate in S-phase (7;14). Cell cycle arrest allows time for DNA damage to be assessed and for nucleotide excision repair-related proteins to remove DNA damage and facilitate replication (3). Or, if DNA damage is too extensive, the cell(s) can undergo apoptosis (reviewed in (15)).
Insufficient DNA damage repair results in mutagenesis, the most common of which is Trp53 mutation

Hallmark mutations of UV-induced DNA damage, C→T or CC→TT transitions occur mainly at pyrimidine dimers (16). These transitions most commonly occur at CpG (5’-CG-3’) sequences where cytosines can be spontaneously deaminated or preferentially targeted by carcinogens (17-19).

Mutations of Trp53, the gene that encodes for the p53 tumor suppressor, are the most common and earliest known mutations in non-melanoma skin cancer, occurring in between 12-58% of SCC and BCC (20). p53 is a transcription factor that regulates the expression of many different genes involved in cell-cycle arrest, apoptosis, senescence,
DNA repair, and angiogenesis. It also stimulates an autoregulatory negative feedback loop by promoting transcription of Mdm2, a negative regulator of p53. Mdm2 exports p53 from the nucleus, and acts as an E3 ligase, targeting p53 for proteasomal degradation (reviewed in (21)).

The most common Trp53 mutations in UV-exposed skin are UV signature mutations (22;23) in the DNA binding region, resulting in a dominant negative mutant p53 with an increased half-life (24-29). Dominant negative mutant p53 blocks transcription factor activity of wild type p53 (21), depriving cells of its important tumor suppressor function and increasing cancer risk.

**UV irradiation causes skin cancer**

The major cause of non-melanoma skin cancer is exposure to UV-irradiation. Non-melanoma skin cancer is the most prevalent cancer in the United States and the National Cancer Institute (NCI) estimates that in 2007 over one million new cases of non-melanoma skin cancers were diagnosed in the United States and less than 2,000 (<1% new diagnosed cases) deaths could be contributed to non-melanoma skin cancers (http://www.cancer.gov/cancertopics/types/skin). Though non-melanoma skin cancers are not commonly life threatening, they are among the most costly to treat due to their high incidence (30). In 2001, Chen, et al. estimated the cost for non-melanoma skin cancer treatment at $650 million for the entire United States’ population (31). The majority (70-80%) of diagnosed non-melanoma skin cancer cases are basal cell carcinomas (BCC). BCC cells have the columnar phenotype of the cells in the basal layer of the epidermis. The other type of non-melanoma skin cancer is squamous cell
carcinoma (SCC) which, like the keratinocytes in the stratus corneum, has a more squamous phenotype. Both BCC and SCC arise from keratinocytes in the skin.

Carcinogenesis generally follows the multistage tumorigenesis model (Figure 2, (32;33)). If UV-induced DNA damage is not correctly repaired, a genetic mutation can become fixed resulting in an initiated cell. This cell undergoes clonal expansion through the addition of growth stimuli and becomes a benign tumor. Additional gene mutations can result in the formation of a malignant and eventually metastatic tumor. UV-irradiation is capable of both causing DNA damage, which can lead to an initiated cell, and providing growth stimuli through multiple mechanisms (34-37).

![Figure 2. The multistage tumorigenesis model.](image)

Schematic representation of multistage tumorigenesis model. UV-irradiation can result in both mutagenesis and growth stimuli, thereby promoting skin tumorigenesis.

SCC develop through the model described above but BCC are thought to develop through a slightly modified version of the multistage tumorigenesis model. BCC appear to develop into a malignant tumor directly from an initiated cell. Both BCC and SCC
have low rates of metastasis. However, immunosuppressed patients (i.e. transplant recipients) have increased rates of BCC (10 times) and SCC incidence (up to 250 times that of the normal population) as well as increased rates of recurrence and SCC metastasis (5-8%, reviewed in (38)).

**UV irradiation indirectly activates receptor tyrosine kinases, including Erbb family members**

One way that UV-irradiation stimulates proliferation is through activation of receptor tyrosine kinases (RTKs). RTKs such as members of the Erbb family, are indirectly activated by UV-irradiation through the inhibition of protein tyrosine phosphatases by reactive oxygen species (ROS) (39;40). Protein tyrosine phosphatases (PTPs) normally maintain low levels of receptor phosphorylation. ROS oxidize a critical cysteine residue in the active site of PTPs resulting in their inactivation and increased RTK activation (Figure 3, (41)). The aberrant activation of members of the Erbb family by UV-irradiation can result in an increase of tumor promoting growth stimuli. Mitogenic ligands (i.e. TGFα) that activate the Erbb receptors result in increased mRNA levels of membrane-bound ligand precursors (42). In addition, UV can stimulate the processing of TGFα from membrane-bound precursors through the activation of cell surface proteases (43;44). In this way UV promotes autocrine signalling by the Erbb family through a positive feedback loop (Figure 3).
Figure 3. UV regulation of Erbb phosphorylation and autocrine signaling.

Schematic representation of UV regulation of Erbb family activation (i.e. EGFR, Erbb2) and growth stimuli through the deactivation of protein tyrosine phosphatases (PTPs) by ROS and the activation of proteases which enhance autocrine signaling through cleavage of membrane-bound ligand precursors.

Erbb2 is a member of the Erbb family of RTKs

One member of the Erbb family of RTKs that is activated by UV-irradiation is Erbb2. In 1985, Erbb2 was isolated from DNA from rat neuroblastomas and was known to code for tumor antigen p185, termed NEU (45). It was shown that NEU had homology to, but was not derived from, Erbb, or epidermal growth factor receptor (EGFR), and was therefore named Human EGF receptor 2 (HER2) (46). Also in 1985, Semba, et al. discovered an Erbb-like gene (47) with protein tyrosine kinase activity (48) which was named Erbb2. In 1987 Di Fiore, et al. showed that neu is the rat homolog of human erbB-2 by comparing sequences and chromosomal mappings (49).
The Erbb family of receptor tyrosine kinases is made up of four members: EGFR, Erbb2, Erbb3, and Erbb4, which are expressed in tissues of epithelial, mesenchymal and neuronal origin (50). Each of these members has a single transmembrane domain, an extracellular binding domain, and a cytoplasmic protein tyrosine kinase domain (51). Activation of these receptors begins with the binding of a ligand to the extracellular domain. Ligands that bind to the Erbb family of receptors are referred to as epidermal growth factor (EGF)-related peptide growth factors that are processed from transmembrane precursors (44). These growth factors include EGF, amphiregulin (AR), transforming growth factor-α (TGF-α), betacellulin (BTC), heparin-binding EGF (HB-EGF), epiregulin (EPR), and neuregulins (NRG) all of which have different receptor specificities (summarized in Table 1). The binding of a ligand to the extracellular domain directs the receptor to undergo homo- or hetero-dimerization with another member of the Erbb family. Dimerization of receptors results in auto- or trans-phosphorylation of the intracellular tyrosine kinase domain. Each receptor has multiple sites which are phosphorylated based on both the ligand and dimerization partner. After dimerization occurs, adaptor proteins that contain either Src homology-2 (SH2) or phosphotyrosine binding domains (PTB) are recruited to the phosphorylated receptors. The adapter protein(s) recruited depends on the location of the phosphorylation site and therefore, different ligand/receptor/phosphorylation site combinations lead to diversification of signal transduction.

The composition of homodimers is limited because Erbb3 has a defective kinase (52) and Erbb2 has no known ligand. Therefore, these receptors are reliant on heterodimerization with other Erbb family members to effectively trigger a signaling
cascade under normal conditions. Erbb2 is the preferred dimerization partner of all other Erbb family members and increases potency of signaling by enhancing the association with adapter proteins (53), decreasing ligand dissociation rates (54;55) and internalization (56), and increasing recycling of receptors that might otherwise be targeted for lysosomal degradation (57).

Table 1. Erbb family ligand specificity.

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Ligand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR</td>
<td>EGF, AR, TGF-α</td>
</tr>
<tr>
<td>Erbb2</td>
<td>--</td>
</tr>
<tr>
<td>Erbb3 &amp; Erbb4</td>
<td>NRG-1, NRG-2</td>
</tr>
<tr>
<td>Erbb4</td>
<td>NRG-3, NRG-4</td>
</tr>
<tr>
<td>EGFR &amp; Erbb4</td>
<td>BTC, HB-EGF, EPR</td>
</tr>
</tbody>
</table>

**Erbb2 regulates normal cellular processes**

Erbb2 is involved in the activation of several signaling pathways that regulate normal cellular processes such as cell proliferation, survival, death, differentiation, adhesion, migration, inflammation, and angiogenesis (58;59). Signalling pathways activated by Erbb2 include phosphatidylinositol 3-kinase (PI3K)/Akt, Ras-mitogen-activated protein kinase (MAPK), phospholipase C (PLC)-protein kinase C (PKC), Src, and Jak/Stat (reviewed in (60;61)). Upon activation of these signaling pathways, Erbb2 has an essential role in organ development and function. Erbb2 null mice die midgestation (62), due to defects in cardiac and neuromuscular junctions (63;64). In 2002, Chan, et al. demonstrated that Erbb2 tyrosine kinase activity was necessary for both normal cardiac and neural development (65). Other studies have demonstrated that
Erbb2 is necessary for the prevention of dilated cardiomyopathy, a side effect of Erbb2-targeted therapeutics (66;67).

**Erbb2 is a therapeutic target in a number of cancers**

Erbb2 has been found to be overexpressed in a number of internal cancers, including, breast, colon, and ovarian cancers. Overexpression of Erbb2 in these cancers is generally indicative of aggressive cancer and a poor prognosis. Because of Erbb2’s role in cancer development and progression, targeted therapies have been developed. These therapies include trastuzumab (Herceptin), a humanized Erbb2 monoclonal antibody targeted to the extracellular domain, and small molecule tyrosine kinase inhibitors (TKIs) which prevent receptor activation. The mechanism of action of trastuzumab is unknown, despite its widespread use. It has been suggested that trastuzumab prevents “shedding” of the extracellular domain of Erbb2 by proteolytic cleavage or decreases signaling by mediating internalization and degradation of the receptor (reviewed in (68)). Unfortunately, trastuzumab is only effective in about 30% of Erbb2-overexpressing breast cancers as a single agent. Though more effective when paired with chemotherapeutics, there is an increased risk for cardiotoxicity (69). In addition, some cancers acquire resistance against trastuzumab, limiting its use. Hsieh and Moasser (2007) suggest that due to incomplete inhibition of HER2 signaling, the potent HER2-HER3 heterodimer may still be able to potentiate growth signals through the PI3K/Akt pathway thereby making it necessary to develop more potent Erbb2-targeted TKIs (70). Clinical trials are currently underway for several small molecule inhibitors such as Lapatinib, a small molecule duel reversible inhibitor of EGFR (HER1) and HER2
tyrosine kinase activity. Lapatinib has shown promise when used in combination with trastuzumab and is currently in phase III clinical trials (reviewed in (68)).

Why study Erbb2’s role in skin cancer?

EGFR, Erbb2, Erbb3, but not Erbb4 are expressed in the keratinocytes of the epidermis. In the basal keratinocytes of the epidermis, Erbb2 has a cytoplasmic localization, while in suprabasal keratinocytes it is localized to the cell surface (71;72). Several groups have reported dramatic phenotypes in Erbb-overexpressing transgenic mice, which include severe hyperplasia and spontaneous papilloma formation (73-76). There are conflicting results regarding Erbb2 protein levels in BCC and SCC (71;77), but Erbb2 mRNA and protein has been detected in human skin and non-melanoma skin cancers (78) and is activated upon UV-irradiation (Figure 7). Despite normal Erbb2 levels, UV-induced activation amplifies Erbb2’s effects as an oncoprotein in the skin.

We recently demonstrated that UV-irradiation activates Erbb2 both *in vitro* and *in vivo* as measured by the phosphorylated receptor (79). Inhibition of Erbb2 using the tyrphostin inhibitor AG825 reduces DNA synthesis both in sham- and UV-irradiated keratinocytes (79). In addition, inhibition of Erbb2 causes S-phase arrest, during which the cells respond to and repair UV-induced DNA damage. Inhibition of Erbb2 in sham- and UV-irradiated keratinocytes also decreases Cdc25A immunoreactivity, suggesting that Erbb2 maintains Cdc25A levels. These results suggest that Erbb2 may regulate the ATR pathway.

Previously, it has been demonstrated that Akt phosphorylates Chk1 at serine 280, an inhibitory phosphorylation site (80;81). Since Chk1 targets Cdc25A for degradation resulting in an S-phase arrest, an inactive Chk1 would result in maintenance of Cdc25A
and S-phase progression after DNA damage. One of the signaling pathways that Erbb2
activates after UV-irradiation is the PI3K/Akt survival pathway. Therefore, Erbb2 is
suspected to regulate the ATR pathway through the PI3K/Akt pathway. Through this
mechanism, the UV-induced activation of Erbb2 could prevent the phosphorylation and
degradation of Cdc25A and therefore prevent a cell cycle arrest and reduce the efficiency
of DNA damage repair (Figure 4). However, it has not yet been determined whether
Erbb2 regulates the ATR DNA damage pathway through this mechanism.

Figure 4. Potential mechanism for Erbb2 regulation of the ATR DNA damage
response pathway.
Schematic representation of the potential mechanism in which Erbb2 might regulate
the cell’s response to UV-induced DNA damage. Erbb2 activates the PI3K/Akt
pathway which may cause the deactivation of Chk1, ultimately preventing cell cycle
arrest. The lack of cell cycle arrest reduces the efficiency of DNA damage repair
and increases the probability of mutagenesis.

To determine whether S-phase arrest suppresses tumorigenesis, CD-1 mouse skin
was treated with AG825 or DMSO (control) and was sham- and UV-irradiated (two
exposures totaling 20kJ/m²). UV-irradiated DMSO-treated mice formed about twice as many tumors that were about twice the volume of the tumors formed in AG825-treated mice 12 weeks after the final UV exposure, suggesting that Erbb2 promotes UV-induced skin tumorigenesis. Although the tyrphostin inhibitor AG825 is about 60 times more specific for Erbb2 than EGFR (69,70), off-target effects make the inhibition of Erbb2 by AG825 an imperfect system for studying the function of Erbb2. Therefore, a skin-targeted conditional Erbb2 null mouse model was developed to study Erbb2’s involvement in the response of the skin to UV-irradiation.

Since cell cycle arrest increases the efficiency of DNA damage repair, we hypothesized that promotion of S-phase progression by Erbb2 after UV-irradiation limits DNA damage repair and results in increased mutagenesis. In order to test this hypothesis, Erbb2 mutant and littermate controls were exposed repeatedly to UV-irradiation and euthanized prior to tumor development. The role of Erbb2 in the regulation of cell cycle progression, DNA damage repair, and mutagenesis was investigated. Genetic ablation of Erbb2 in the skin results in a compensatory upregulation of Cdc25A which may have implications for the long term use of Erbb2-targeted therapeutics. This work also suggests that Erbb2 has a role in the regulation of UV-induced DNA damage repair and mutagenesis independent of its regulation of cell cycle progression.
Chapter 2: Materials and Methods

Animals

Erbb2 floxed (Erbb2^{fl/fl}) mice were generously provided by Dr. Ulrich Mueller (Scripps Institute, La Jolla, CA); loxP sites were inserted on either side of the first coding exon of Erbb2 as described in (82). These mice were crossed with transgenic mice on an FVB/N background in which Cre recombinase expression was driven by the Keratin 14 promoter (K14 Cre) (The Jackson Laboratory, Bar Harbor, ME) to create Erbb2 mutant mice (Erbb2^{fl/fl cre^+}) and littermate controls (Erbb2^{fl/fl cre^-}). All mice were maintained in the Creighton University Animal Facility and were fed with Purina lab chow (Nestlé Purina Pet Care, St. Louis, MO) and given water ad libitum. All animal procedures were performed in accordance with American Association of Laboratory Animal Care guidelines and approved by the institutional animal care and use committee (IACUC).

Keratinocyte Culture

Newborn pups were euthanized and sterilized with betadine and 70% ethanol. Skin was removed as described in (83) and floated on 0.25% trypsin (Invitrogen) with 10% versene (Invitrogen) overnight at 4°C. The epidermis and dermis were separated. Epidermises from mice of the same genotype were pooled and minced using sterile scissors. Cells were plated in sterile polystyrene 60 mm dishes (Becton Dickinson) in minimum essential media (S-MEM, Invitrogen), containing 8% fetal bovine serum (FBS, Lifeblood Medical, Adelphia, NJ) and 1% Penicillin/Streptomycin (Invitrogen), referred to as HiCa medium. The day after plating and every two to three days thereafter, the cells were refed with S-MEM containing a mixture of unchelexed and chelexed FBS (Lifeblood...
Medical) with a calcium concentration adjusted to 0.05 mM, and 1% penicillin/streptomycin (Invitrogen), referred to as LoCa medium. Serum was chelexed to reduce the calcium concentration using Chelex 100 Resin (Bio-Rad Laboratories, Hercules CA). The calcium level of the FBS was measured by Dr. U. Lichti (NCI).

**Ultraviolet Irradiation**

Ultraviolet (UV) radiation was generated by Ultraviolet-B TL 40W/12 RS Bulbs (Philips, Somerset, NJ), which emit approximately 30% UVA, 70% UVB, and <1% UVC, as measured using Oriel Goldilux radiometric photodetector probes (Newport Corporation, Irvine, CA). On the day of UV-irradiation, the hair on the dorsal skin was clipped using a Wahl Animal Trimmer (Wahl Clipper Corporation, Sterling, IL) and shaved with a microscreen wet/dry electric shaver (Panasonic, Kadoma, Osaka, Japan). Once shaved, mice were placed under the UV bulbs, receiving between 0.5-3.0 kJ/m². Keratinocytes in culture were covered with phosphate buffered saline (PBS) containing 0.05 mM CaCl₂ and were placed under the lamp, receiving 600 J/m² UV. Protein lysate from UV-exposed human skin was generously provided by Dr. Gary Fisher (University of Michigan, study 1087). Human skin was sham- or UVB-irradiated at twice the minimal erythema dose (2MED, measured for each patient, ranging between 0.6 kJ/m² and 1.0 kJ/m²) as described in (84).

**Virus infection**

Keratinocytes were cultured until they reached 60-70% confluency. The cells were incubated with empty or Cre adenoviruses (a generous gift from Dr. Stuart Yuspa (NIH)) at 30 plaque forming units per cell (PFU/cell), in S-MEM with 4 µg/mL polybrene.
(Sigma-Aldrich, St. Louis, MO) for 45 min. LoCa was added to the cells and virus mixture. Cells were infected 24 h prior to UV-irradiation.

**Experimental Design**

Age matched *Erbb2* mutant mice and littermate controls (described above) were sham- or UV-irradiated 43 times over 39 weeks as per the procedure described above. Mice in UV- and sham-irradiated groups were injected with bromodeoxyuridine (BrdU, Sigma, St. Louis, MO) 1 h prior to euthanization (approximately 2.25 mg per 30 g body weight). Mice were euthanized 1, 12, 18, 36, or 72 h after the final UV exposure. Pieces of whole skin were flash frozen on dry ice. Dorsal skin sections were also fixed in 70% ethanol or 10% buffered formalin. Paraffin embedded blocks and slides were prepared by American Histolabs (Gaithersburg, MD).

**Immunofluorescence**

Skin sections were incubated with antibodies recognizing BrdU (1:3, Becton Dickinson), thymine dimer (clone KTM53 (recognizing all cyclobutane dimers), 1:1000, Kamiya Biomedical Company, Seattle, WA), and p53 (1:300, Santa Cruz, Santa Cruz, CA). One section per slide was a negative control that was incubated in 3% bovine serum albumin (Fisher Scientific, Fair Lawn, NJ) in PBS instead of the primary antibody. For BrdU and cyclobutane dimer immunofluorescence, ethanol fixed, paraffin embedded sections were used. Slides were incubated in 2N HCl and concentrated Trypsin (Sigma, 1 mg Trypsin per mL distilled water) for 5 min each. Sections were blocked in 10% goat serum prior to overnight incubation with the primary antibody. Following primary antibody incubation, sections were incubated with biotinylated F(Ab)\(_2\) fragment goat anti-mouse secondary
antibody (Jackson ImmunoResearch, West Grove, PA), Texas-red Streptavidin (Vector Laboratories, Burlingame, CA), and 4',6-Diamidino-2-Phenylindole (DAPI)-containing mounting media, consisting of 50% glycerol in PBS with 0.01g/mL propyl gallate (Sigma) and 1.5 µg/mL DAPI (Molecular Probes, Invitrogen, Carlsbad, CA). For quantification of immunofluorescence, the investigator was blinded to the identity of the samples. BrdU was quantified by counting BrdU-positive cells and DAPI-positive basal cells at ten randomly selected fields using a 20x objective and the BrdU labeling index is reported as the percentage of BrdU-labeled basal cells. The intensity of cyclobutane dimer labeling was quantified using ImageJ software (http://rsb.info.nih.gov/ij/) to determine the mean pixel intensity. The mean pixel intensity of the background was subtracted from the overall fluorescence for three to five randomly selected regions of each skin section. For p53 immunofluorescence, formalin fixed paraffin embedded sections were used and antigen retrieval was performed through alternating heating and cooling cycles in 0.9% Antigen Unmasking Solution (Vector Laboratories). Sections were blocked in 10% goat serum with 1% non-fat milk (Hy-Vee) prior to overnight incubation with the primary antibody. Following primary antibody incubation, the sections were incubated with Alexa Fluor 488-conjugated secondary antibody (Invitrogen), and DAPI-containing mounting media. p53 labeling was quantified by counting the number of p53-positive cells per p53-positive focus and the number of p53-positive foci per mm skin. Statistics were calculated using a Student’s t-test and results were deemed significant for p≤0.05.
**Immunoblotting**

Flash frozen whole skin from mice was homogenized using a Tissue Master 125 (OMNI International, Marietta, GA) in lysis buffer containing 10 M Tris (pH 7.4), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, Complete Protease Inhibitor Cocktail (Roche, Mannheim, Germany), 1 mM sodium orthovanadate (Na$_3$VO$_4$), 1.5 µM EGTA, and 10 µM sodium fluoride (NaF). Protein was loaded and separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (Bio-Rad Laboratories) and transferred to nitrocellulose membranes (Bio-Rad Laboratories). The evenness of loading and transfer was determined by Ponceau S staining (Sigma) and by immunoblotting for actin (*in vitro*) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH, *in vivo*). Membranes were blocked with 5% nonfat dry milk (Hy-vee, Des Moines) in PBS, incubated overnight with antibodies recognizing Erbb2 (1:200, Upstate, Temecula, CA), phospho-Erbb2 (Tyrosine 1248, Upstate), proliferating cell nuclear antigen (PCNA, 1:800, Dako, Glostrup, Denmark), GAPDH (1:1000, Novus, Littleton, CO), Actin (1:10,000, Sigma), or Cdc25A (1:500, Santa Cruz), then incubated with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling), and chemiluminescent reagents (Pierce, Rockford, IL) prior to autoradiography. Protein levels were quantified by densitometry using 1DScanEX Software (Scanalytics, Fairfax, VA). Statistics were calculated using a Student’s *t*-test and results were deemed significant for p≤0.05.
**Flow Cytometry**

Cultured keratinocytes were removed from 60 mm polystyrene dishes after sham- or UV-irradiation using 0.25% Trypsin-EDTA (Invitrogen), incubated with Vindelov’s solution (85), containing 3.5 mM Tris base (pH 7.6), 10 mM NaCl, 10 µg/mL Ribonuclease A (Sigma), 75 µg/mL propidium iodide (Sigma), 0.1% Igepal (Sigma), and filtered through 35 µm nylon filters into 5 mL polystyrene round bottom tubes (Becton Dickinson). For flow cytometry using *in vivo* skin samples, three 60 µm sections were cut from formalin-fixed paraffin embedded blocks. The sections were dewaxed with xylene and rehydrated with decreasing concentrations of ethanol (100%, 90%, 70%, 50%, and distilled water). Cells were then digested in 0.05% pepsin (Sigma) in PBS with pH 1.5 and incubated with Vindelov’s Solution (85). Flow cytometry analysis was performed in the Creighton Flow Cytometry Core Lab on the FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ) using FL2 channel (585-42 bandpass filter). Single cells were identified by measuring area (FL2-A) and width (FL2-W) and data for at least 10,000 singlets for each sample were collected in list mode data files using Cell Quest Pro software (Becton Dickinson). A histogram for FL2-A intensity was plotted for single cells and cell cycle distributions were determined using ModFit LT 3.1 software (Verity Software House, Topsham ME). Statistics were calculated using a Student’s *t*-test and results were deemed significant for *p* ≤ 0.05.
Chapter 3: Results

*Skin-targeted Erbb2 mutant mice were developed to overcome off-target effects of other models*

To investigate the influence of Erbb2 activation on the response of the skin to UV, a skin-targeted conditional *Erbb2* null (*Erbb2* mutant) mouse was developed. This model was used to test the hypothesis that promotion of S-phase progression by Erbb2 after UV-irradiation limits DNA damage repair and results in increased mutagenesis after chronic UV-irradiation.

To generate *Erbb2* mutant mice, mice with two *Erbb2* floxed alleles (*Erbb2*\(^{fl/fl}\)) were crossed with mice in which Cre recombinase expression is driven by the Keratin 14 (K14) promoter. In mice, expression of K14 begins in the basal keratinocytes of the epidermis at E14.5 (86), resulting in the expression of Cre recombinase and the genetic ablation of *Erbb2* in the epidermis (Figure 5A). The *Erbb2* mutant mice were healthy and viable (Figure 5B). Immunoblotting confirmed that the average Erbb2 immunoreactivity was reduced approximately 95% in the keratinocytes of *Erbb2* mutant skin (*Erbb2*\(^{fl/fl}\) cre\(^{+}\)) when compared to Cre-expressing mice that lack *Erbb2* floxed alleles (*Erbb2*\(^{wt/wt}\) cre\(^{-}\), Figure 5C).

For the *Erbb2* mutant mice used in the experiments, the genotypes were determined by polymerase chain reaction analysis and confirmed by immunoblotting (as in Figure 6). Littermate controls lacked Cre recombinase expression, but contained both *Erbb2* floxed alleles (*Erbb2*\(^{fl/fl}\) cre\(^{-}\)). On average, there was a 95% reduction of Erbb2 immunoreactivity in sham-irradiated *Erbb2* mutant mice compared to littermate controls.
Figure 5. Generation of Erbb2 mutant mice.

A. Skin-targeted conditional Erbb2 null (Erbb2 mutant) mouse were generated by crossing Erbb2<sup>fl/fl</sup> mice with mice in which expression Cre recombinase is driven by the Keratin 14 (K14) promoter. B. Photograph of an Erbb2 mutant (Erbb2<sup>fl/fl cre</sup>+<sup>+</sup>) mouse. C. Erbb2 protein immunoreactivity in 8 day old transgenic mice expressing Cre recombinase in the skin (left panel). Quantification utilized densitometry analysis for multiple replicates (described in Materials and Methods, right panel).
Figure 6. Erbb2 immunoreactivity is decreased in Erbb2 mutant skin. 
Protein lysate from groups of sham-irradiated skin from Erbb2 mutant mice (Erbb2^{fl/fl} cre^+) and littermate controls (Erbb2^{fl/fl} cre^-) was used for immunoblotting (N=2 mice shown). Numbers indicate mean densitometry for the group after normalizing each sample to GAPDH.

**Genetic ablation of Erbb2 results in small differences in cell cycle progression after UV-irradiation**

Non-melanoma skin cancer is caused by chronic exposure to UV-irradiation. Previous research has implicated UV-activated Erbb2 in the suppression of S-phase arrest after UV-irradiation, which impairs cells’ abilities to repair DNA damage or undergo apoptosis. UV activates Erbb2 both *in vivo* and *in vitro* and in both mouse and human skin ((79) and Figure 7A and B). To test the hypothesis that the ablation of Erbb2 results in an increased S-phase arrest after UV-irradiation, age-matched groups of Erbb2 mutant mice and littermate controls (N=25) were exposed to sham- or UV-irradiation, totaling 26 kJ/m^2 (43 exposures, 0.5-3 kJ/m^2 per week) over the course of 39 weeks. Mice did not develop any visible skin lesions and were euthanized at several timepoints after the final (1 kJ/m^2) UV exposure. The ultimate goal of this experiment was to investigate Erbb2’s role in the regulation of cell cycle progression, DNA damage repair, and mutagenesis in chronically UV-exposed skin. The experimental design, including groups of sham- and UV-irradiated Erbb2 mutant and littermate controls, is summarized in Figure 8A.
DNA content flow cytometry was used to determine the cell cycle distribution of keratinocytes in the skin after chronic UV-irradiation (Figure 8B). In skin from both Erbb2 mutant mice and littermate controls, the percentage of cells in G0/G1-phases declined by about 6% in the first 36 h after UV-irradiation (Figure 8B, left panel). This decrease in G0/G1-phase cells was associated with a corresponding increase in the percentage of S-phase cells (Figure 8B, middle panel). In Erbb2 mutant skin, the percentage of S-phase cells increased by about 3% when compared to UV-exposed control skin 12 h after UV-irradiation (Figure 8B, middle panel) with a corresponding decrease in G2/M-phase cells (Figure 8B, right panel). 18 h after UV-irradiation, there was an increase in G2/M-phase cells (~2%, Figure 8B, right panel) with a corresponding decrease in G0/G1-phase cells (Figure 8B, left panel). The increase in S-phase cells 12 h after UV-irradiation was consistent with the S-phase accumulation seen in keratinocytes treated with AG825 (in vivo and in vitro, unpublished data) although statistical
significance could not be determined due to insufficient sample size. In addition, at 18 h after UV-irradiation the percentage of cells in G\textsubscript{2}/M phase were significantly increased (~3.5%, Figure 8B, right panel) and the G\textsubscript{0}/G\textsubscript{1}-phase cells were significantly decreased (~2%, Figure 8B, left panel) in Erbb2 mutant skin compared to littermate controls. Based on this analysis, small (<5%) but statistically significant differences in cell cycle progression exist between the control and Erbb2 mutant mice after UV-irradiation.

A.

![Diagram of experiment timepoints](image)

B.

![Graphs of cell cycle progression](image)

Figure 8. Cell cycle progression from Erbb2 mutant and littermate controls after receiving 43 UV-exposures totaling 26 kJ/m\textsuperscript{2}.

Groups of mice were exposed to sham- and UV-irradiated 43 times over a period of 39 weeks (totaling 26 kJ/m\textsuperscript{2}) and were euthanized at the indicated timepoints. A. Schematic representation of experiment. B. Flow cytometry for DNA content was performed on formalin-fixed paraffin embedded blocks containing sham- and UV-irradiated mouse skin as described in Materials and Methods (N\textgeq3 except 12 h (N=2); * p\leq0.05; +, t-test could not be performed due to insufficient number of samples).
To determine whether the increase in S-phase cells is due to a cell cycle arrest (as in AG825 treated skin) or increased DNA synthesis, BrdU-labeling was quantified using immunofluorescence. Representative images of BrdU immunofluorescence are shown in Figure 9A. The number of BrdU-positive basal cells and DAPI-labeled basal cells were quantified in photomicrographs like those shown in Figure 9A to obtain the results presented in Figure 9B. In control skin lacking Cre recombinase expression, the number of basal cells undergoing DNA synthesis was increased by 18 h after UV-irradiation (~10%, Figure 9B).

By contrast, in Erbb2 mutant skin, the percentage of basal cells in which DNA synthesis was occurring increased by 12 h after UV-irradiation (~10%, Figure 9B), though statistical significance could not be determined due to insufficient sample size. These results suggest that in Erbb2 mutant skin, the increase in S-phase cells observed in the flow cytometry analysis was due to increased DNA synthesis instead of a cell cycle arrest (Figure 9B).

Since an S-phase arrest was not observed in the skin from Erbb2 mutant mice, similar Cdc25A immunoreactivity was expected in the skin of Erbb2 mutant mice and littermate controls. As anticipated, Cdc25A immunoreactivity in the Erbb2 mutant mice was similar to that of the littermate controls after UV-irradiation consistent with normal cell cycle progression (Figure 10). Although the average Cdc25A immunoreactivity in sham-irradiated Erbb2 mutant skin was reduced the signal for Cdc25A was quite variable in these samples.

In addition, immunoblotting for proliferating cell nuclear antigen (PCNA), a protein involved in DNA synthesis, was performed as another measure of DNA synthesis.
A.

![Sham UV (18 h) Red: BrdU; Blue: DAPI](image)

B.

![Graph showing DNA synthesis](image)

Figure 9. DNA synthesis after UV-irradiation quantified by BrdU labeling index.

Groups of mice were sham- or UV-irradiated (43 exposures totaling 26 kJ/m²). Mice were injected with BrdU 1 h prior to euthanization as described in Materials and Methods. Bromodeoxyuridine (BrdU) immunofluorescence was performed on skin sections from these mice. A. Representative BrdU immunofluorescence photomicrographs illustrating the increase in DNA synthesis after UV-irradiation (scale bar 40 µm). B. Mice injected with BrdU were euthanized at the indicated timepoints. DNA synthesis was quantified as the percentage of BrdU-labeled basal cells (N≥3 except 12 h (N=2); * p≤0.05; +, t-test could not be performed due to insufficient number of samples).

The average PCNA immunoreactivity in skin from Erbb2 mutant mice was decreased in sham-irradiated mice and increased 12 h after UV-irradiation when compared to the littermate controls. The increase in PCNA immunoreactivity 12 h after UV-irradiation suggests increased DNA synthesis, consistent with the BrdU-quantification. Taken together, these results demonstrate that genetic ablation of Erbb2 using the K14 promoter to drive Cre recombinase expression in an Erbb2<sup>0/0</sup> murine...
model does not cause an S-phase arrest after UV-irradiation and DNA synthesis is instead increased 12 h after UV-irradiation.

![Figure 10. Immunoblotting consistent with normal cell cycle progression.](image)

Groups of mice were exposed to sham- and UV-irradiation (43 exposures totaling 26 kJ/m²). Protein lysate was extracted from whole skin as described in Materials and Methods. Immunoblotting was performed on protein lysate from Erbb2 mutant mice and littermate controls euthanized at the indicated timepoints. There were not consistent differences between PCNA and Cdc25A immunoreactivity in skin of Erbb2 mutant and littermate controls (N=2 mice shown). Numbers indicate mean densitometry for the group after normalizing each sample to GAPDH.

**Genetic ablation of Erbb2 improves DNA damage repair after UV-irradiation**

One way that a cell protects against mutagenesis is through efficient repair of UV-induced DNA photoproduccts, such as cyclobutane dimers (16). Therefore, the repair of cyclobutane dimers was deemed an appropriate measurement for the efficiency of DNA repair and was used to test the hypothesis that Erbb2 reduces the efficiency of DNA damage repair. Since an S-phase arrest was not observed in Erbb2 mutant skin after UV-irradiation, improved DNA damage repair efficiency was not anticipated.

DNA damage was quantified by measuring the intensity of cyclobutane dimer immunofluorescence with Image J software. Representative images of the cyclobutane
dimer immunofluorescence are shown in Figure 11A. The majority of nuclei in the epidermis stained positive for cyclobutane dimers by 12 h after UV-irradiation. By 72 h, staining for cyclobutane dimers was weak, suggesting that UV-induced DNA damage was mostly repaired within 72 h after UV-irradiation. The intensity of cyclobutane dimer labeling was quantified in photomicrographs like those shown in Figure 11A to obtain the results presented in Figure 11B.

![Figure 11A: Cyclobutane dimer (CBD) immunofluorescence illustrates formation of DNA damage after UV-irradiation (12 h) and their eventual repair (72 h, scale bars 40 µm).](image1)

![Figure 11B: DNA damage was quantified by the intensity of cyclobutane dimer staining, as measured using Image J software (described in Materials and Methods, N≥3 except 1h and 12 h (N=2), a.u. arbitrary units; * p≤0.05; +, t-test could not be performed due to insufficient number of samples).](image2)

**Figure 11. UV-induced DNA damage quantified by cyclobutane dimer immunofluorescence intensity.**

Groups of mice were exposed to sham- and UV-irradiation (43 exposures totaling 26 kJ/m²). Skin sections were mounted on slides and stained for cyclobutane dimers. A. Cyclobutane dimer (CBD) immunofluorescence illustrates formation of DNA damage after UV-irradiation (12 h) and their eventual repair (72 h, scale bars 40 µm). B. DNA damage was quantified by the intensity of cyclobutane dimer staining, as measured using Image J software (described in Materials and Methods, N≥3 except 1h and 12 h (N=2), a.u. arbitrary units; * p≤0.05; +, t-test could not be performed due to insufficient number of samples).

Cyclobutane dimers were detected 1 h after UV-irradiation. Reduction of cyclobutane dimer-labeling intensity began by 12 h and 18 h after UV-irradiation in skin from Erbb2 mutant and littermate controls, respectively. The average cyclobutane dimer
immunofluorescence intensity 36 h after UV-irradiation in the Erbb2 mutant was similar to that of sham-irradiated skin, suggesting that DNA damage was fully repaired (Figure 11B). In control skin lacking Cre recombinase expression, cyclobutane dimer-label intensity was not fully reduced until 72 h after UV-irradiation (Figure 11B). These results suggest that DNA damage repair occurs more quickly in the skin of Erbb2 mutant mice indicating improved efficiency. However, these results are surprising given that no S-phase arrest was observed in Erbb2 mutant skin after sham- or UV-irradiation.

*p53-positive foci are smaller in UV-irradiated skin from Erbb2 mutant mice*

Trp53 mutations are the most common earliest known mutations in non-melanoma skin cancer, occurring in 12-58% of SCC and BCC (20). Previous reports have documented the association of Trp53 mutations with an increased half-life of the protein in UV-exposed mouse skin (24-29). In addition, p53 immunostaining has been used to quantify UV-induced mutagenesis and predict the cancer risk in normal and chronically UV exposed skin (87-89). The vast majority of UV-induced skin tumors in mouse skin are SCC (90), ~50% of which contain p53 mutations (reviewed in (91)). UV-induced ras mutations occurs in SCC at a lower percentage rate (10-20%) though chemically induced skin tumors (i.e. di-methyl-benzanthracene (DMBA)/ 12-O-tetradecanoylphorbol-13-acetate (TPA)) are ras-dependent (reviewed in (91)). p16/CDKN2A mutations occur in about 24% of SCC (92) and PTCH deletion occurs in about 70% BCC but not commonly SCC (reviewed in (91)). Therefore, quantification of mutant p53 was used to test the hypothesis that genetic ablation of Erbb2 results in decreased mutagenesis. Although an increased S-phase arrest after UV-irradiation was
not detected in skin from *Erbb2* mutant mice compared to littermate controls, decreased mutagenesis could result from the improved DNA damage repair efficiency observed in *Erbb2* mutant skin.

Figure 12. Mutagenesis quantified by p53 immunofluorescence.

Groups of mice were exposed to sham- and UV-irradiation (43 exposures totaling 26 kJ/m²). Skin sections were mounted on slides and stained for p53. A. Representative images of p53 immunofluorescence after UV-irradiation (arrows indicate several p53 positive cells, scale bar 20 µm). B. Number of p53 positive foci per mm skin. There was no statistically significance difference between groups (N=11 mice). C. Number of p53 positive cells per focus (* p ≤ 0.05).

p53 immunofluorescence was performed on sham- and UV-irradiated skin from *Erbb2* mutant mice and littermate controls. p53 visible by immunofluorescence was assumed to be mutant p53 because wild type p53 usually has a short half-life and cannot be detected by immunofluorescence. p53-labeled cells were found in clusters (foci) originating in the basal layers of the epidermis suggesting clonal expansion of a single
cell (Figure 12A). p53 was localized to the nucleus in all cells that stained positive for p53.

Results from mice euthanized between 12 h and 72 h after UV-irradiation were combined in the analysis which included the number of p53-positive foci per unit skin length and average number of p53-positive cells per p53-positive focus. Though the average number of p53-positive foci was decreased in Erbb2 mutant skin by about 50%, there was not a statistically significant difference between the skin from Erbb2 mutant mice and littermate controls (Figure 12B). Interestingly, the number of cells per p53-positive focus was significantly decreased in skin from Erbb2 mutant mice compared to littermate controls (~65%, Figure 12C). This result suggests that Erbb2 promotes proliferation of keratinocytes containing mutant p53.

**Erbb2 mutant mice may adapt to loss of Erbb2 by maintaining Cdc25A**

The discovery that genetic ablation of Erbb2 does not result in the S-phase arrest observed after treatment with AG825 or transfection with an Erbb2-targeted siRNA (Figure 8B and unpublished data) led to an investigation into the cause of these inconsistencies. First, to ensure that the lack of a substantial cell cycle difference was not unique to the in vivo mouse model, DNA content flow cytometry was performed on cultured keratinocytes from Erbb2 mutant mice and littermate controls after sham- and UV-irradiation (Figure 13). Similar to the in vivo model, an increase in S-phase arrest was not observed in UV-irradiated Erbb2 mutant keratinocytes in culture (Figure 13, middle panel). Contrary to our hypothesis, Erbb2 mutant cells display decreased S-phase cells 18 h after UV-irradiation (Figure 13, middle panel) and increased Go/G1-phase cells 22 h after UV-irradiation compared to littermate controls (Figure 13, left panel). The
absence of a large difference in cell cycle progression led to an investigation into why the cell cycle profile in Erbb2 mutant skin is similar to that of littermate controls.

One possible explanation for the absence of an S-phase arrest is that cells lacking Erbb2 compensate for its loss. Since expression of K14 and therefore genetic abrogation of Erbb2 begins at E14.5 (86), it is possible that compensation occurs during the life of the study, or perhaps even by birth. In order to test this possibility Erbb2<sup>fl/fl</sup> keratinocytes in culture were infected with a Cre recombinase adenovirus which reduced Erbb2 immunoreactivity by about 95% (Figure 14). Empty (control) and Cre recombinase virus-infected keratinocytes were exposed to sham- or UV-irradiation 24 h after infection and the cell cycle profile was analyzed using flow cytometry (Figure 15).

![Flow cytometry analysis of cultured keratinocytes from Erbb2 mutant mice and littermate controls.](image)

Figure 13. Flow cytometry analysis of cultured keratinocytes from Erbb2 mutant mice and littermate controls.
Keratinocytes cultured from Erbb2 mutant and littermate controls were exposed to sham- or UV-irradiation (600 J/m<sup>2</sup>). Cells were collected for flow cytometry at the indicated timepoints and analyzed for DNA content (N=4 dishes, * p≤0.05).

In empty virus-infected keratinocytes there was a decrease in G<sub>0</sub>/G<sub>1</sub>-phase cells (~18%, Figure 15, left panel) with a corresponding increase in S-phase (~10%, Figure 15, middle panel) and G<sub>2</sub>/M-phase cells (~8%, Figure 15,
right panel) 22 h after UV-irradiation. In Cre recombinase virus-infected cells there was an increase in S-phase cells (~20%, Figure 15, middle panel) with a corresponding decrease in G\textsubscript{2}/M-phase cells (~20%, Figure 15, right panel) 22 h after UV-irradiation. The S-phase accumulation in the Cre recombinase

![Image of a bar graph showing Erb2/Actin densitometry](image)

**Figure 14.** Cre recombinase infection of Erb2\textsuperscript{fl/fl} keratinocytes reduces Erb2 immunoreactivity.

Cultured keratinocytes from Erb2\textsuperscript{fl/fl} Cre\textsuperscript{-} mice were infected with an empty or Cre adenovirus. Immunoblotting was performed on protein lysates from sham-irradiated keratinocytes (left panel). The bar graph (right panel) illustrates Erb2 immunoreactivity based on multiple replicates (N=5 dishes, *** p≤0.001).

![Image of flow cytometry graphs](image)

**Figure 15.** Flow cytometry analysis of virus-infected Erb2\textsuperscript{fl/fl} keratinocytes.

Cultured keratinocytes from Erb2\textsuperscript{fl/fl} Cre\textsuperscript{-} mice were infected with an empty or Cre adenovirus. DNA content flow cytometry analysis was performed on sham- or UV-irradiation (600 J/m\textsuperscript{2}) virus-infected keratinocytes at the indicated timepoints (N=4 dishes, *** p≤0.001).
virus-infected keratinocytes is likely due to a cell cycle arrest instead of increased DNA synthesis since it corresponds to a decrease in the following cell cycle phase (G2/M). However, BrdU quantification should be performed to exclude the possibility of increased DNA synthesis.

A. 

![Graph showing Cdc25A immunoreactivity comparison](image)

**Figure 16. Cdc25A immunoreactivity in Cre recombinase virus-infected Erbb2fl/fl and Erbb2 mutant keratinocytes.**

Keratinocytes were cultured from Erbb2fl/fl cre and Erbb2 mutant mice. Groups of cultured keratinocytes from Erbb2fl/fl cre mice were infected with an empty or Cre recombinase adenovirus (A, B). A. Protein lysate was collected for immunoblotting (left panel). The bar graph illustrates average Cdc25A immunoreactivity after based on multiple replicates (right panel, N=10 dishes, ** p≤0.01). B. Virus-infected keratinocytes were exposed to UV-irradiation (600 J/m²) and protein lysates were collected and used for immunoblotting at the indicated timepoints (representative of 2 immunoblots with similar results). Numbers indicate densitometry after normalizing each sample to GAPDH.

Since Cdc25A is a regulator of CDK2 and the progression through S-phase, Cdc25A immunoreactivity in sham- and UV-irradiated keratinocytes was examined to
determine whether reduced Cdc25A levels could be responsible for the high percentage of S-phase cells in sham-irradiated, Cre recombinase virus-infected keratinocytes. Cdc25A immunoreactivity was decreased in Cre recombinase virus-infected cells after sham- and UV-irradiation (up to 1 h after UV, Figure 16A and B). However, in sham-irradiated keratinocytes from Erbb2 mutant mice, there was no difference in Cdc25A immunoreactivity (Figure 17). These results suggest that Erbb2 mutant cells compensate for loss of Erbb2 by maintaining Cdc25A protein levels.

![Genotype: Erbb2
K14 Cre: - +
Cdc25A
Actin](image)

**Figure 17. Cdc25A immunoreactivity in Erbb2 mutant keratinocytes.** Protein lysate was collected from sham-irradiated keratinocytes from Erbb2 mutant mice and littermate controls for immunoblotting (Left panel). The bar graph illustrates average Cdc25A immunoreactivity based on multiple replicates (N=5 dishes). There are no statistically significant differences between these groups.
Chapter 4: Discussion

Erbb2 is an important player in the diversification and potency of Erbb signaling. The overexpression of Erbb2 in several internal cancers is associated with chemotherapy resistance and a poor prognosis. The importance of Erbb2 in internal cancers has been confirmed by the development and success of Erbb2-targeted therapeutic options. Most studies focus on Erbb2’s role in cells that overexpress Erbb2 as opposed to those that express the protein at normal physiological levels. However, our research suggests that repeated activation of Erbb2 following UV-irradiation could be responsible for producing similar oncogenic results in the skin.

Previous studies in our lab have demonstrated that Erbb2 is activated through an indirect mechanism after UV-irradiation and promotes cell cycle progression. These experiments suggested that Erbb2 could regulate the ATR DNA damage pathway by maintaining Cdc25A, thereby promoting cell cycle progression and preventing S-phase arrest. We have also demonstrated that inhibition of Erbb2 resulted in decreased skin tumorigenesis after chronic UV-exposure, providing further evidence of Erbb2’s role in promoting UV-induced non-melanoma skin cancer. However, these studies were performed using either an inhibitor or siRNA, both of which commonly produce off-target effects. In order to eliminate off-target effects, a skin-targeted conditional Erbb2 null (Erbb2 mutant) mouse was developed in which Erbb2 expression was ablated in the epithelial cells of the skin. This new model was designed to eliminate off-target effects and to test the hypothesis that promotion of S-phase progression by Erbb2 after UV-irradiation limits DNA damage repair and results in increased mutagenesis.
Cell cycle analysis using the *Erbb2* mutant model produced some unexpected results. In contrast to our previous results from Erbb2 inhibitor treated and UV-exposed mice, DNA synthesis and S-phase progression were actually increased in UV-exposed *Erbb2* mutant skin when compared to UV-exposed control mice. Similar analyses performed using *Erbb2* mutant keratinocytes in culture produced a similar response. Consistent with the lack of cell cycle arrest upon genetic ablation of *Erbb2*, Cdc25A was not significantly reduced in keratinocytes from *Erbb2* mutant mice.

These results led us to investigate the inconsistencies between the *Erbb2* mutant and AG825 inhibitor models. Experiments were performed in which the floxed *Erbb2* alleles were ablated by infection of cultured keratinocytes with a Cre recombinase expressing virus. This allowed us to examine the immediate effects of *Erbb2* ablation. Sham- and UV-irradiated Cre recombinase virus-infected keratinocytes produced an S-phase arrest similar to that observed in inhibitor treated keratinocytes and skin. This model for ablation of *Erbb2* expression paralleled the timing of the inhibitor experiments and allowed us to examine the effects of *Erbb2* ablation within the first 48 h after the receptor's signaling was reduced. In addition, Cdc25A immunoreactivity was reduced in sham- and UV-irradiated keratinocytes following viral Cre recombinase expression consistent with the S-phase arrest observed in inhibitor and siRNA treated cells and skin. Because results from the inhibitor and virus infection models are obtained within 48 h of Cre recombinase virus infection or Erbb2 inhibitor treatment, we hypothesize that keratinocytes compensate for prolonged loss of Erbb2 through the maintenance of Cdc25A. Experiments are ongoing in the lab to test this hypothesis.
In addition to the cell cycle analyses, the effects of Erbb2 on repair of UV-induced DNA damage and mutagenesis were also assessed. Although no increase in cell cycle arrest was documented in Erbb2 mutant skin, the efficiency of UV-induced DNA damage repair in Erbb2 mutant skin was improved. Quantification of cyclobutane dimers revealed that DNA damage in Erbb2 mutant skin was repaired within 36 h after UV-irradiation, while damage in skin from littermate controls was not fully repaired until 72 h after UV-irradiation. Because the more rapid DNA damage repair observed in Erbb2 mutant skin cannot be contributed to a cell cycle arrest, Erbb2’s role in reducing the efficiency of nucleotide excision repair appears to involve a mechanism independent of its regulation of the cell cycle. To determine how Erbb2 might be involved in the regulation of nucleotide excision repair, analyses involving the repair factors involved in nucleotide excision repair should be performed in Erbb2 mutant mice.

As in the analysis of DNA repair efficiency, a significant difference in the size or number of p53-positive foci between Erbb2 mutant and littermate controls was not expected due to the lack of an effect of Erbb2 ablation on cell cycle arrest in vivo. Surprisingly, however, the size of p53-positive foci was significantly reduced in UV-exposed Erbb2 mutant skin when compared to littermate controls. We hypothesize that this is the result of decreased clonal expansion of cells containing Trp53 mutations. First, to confirm that p53-positive foci actually contain mutant p53, Trp53 should be sequenced in normal keratinocytes, in cells from p53-positive foci in UV-exposed skin, and in UV-induced skin tumors. Sequencing Trp53 will also confirm clonal expansion and existence of UV-signature mutations (C\rightarrow T or CC\rightarrow TT transitions). The first sequencing targets should be Trp53 codons 270 and 275, which are the most common UV-induced Trp53
mutations in mouse skin and at which pyrimidine dimers are known to form (93). p53
should also be analyzed after fewer UV exposures when p53-positive foci would likely
be smaller and more distinct to ensure that p53-positive foci are not overlapping.

An analysis of the role of Erbb2 in the cell cycle progression, DNA damage
repair, survival, and proliferation of keratinocytes with mutant p53 may prove interesting.
It has previously been demonstrated that wild type p53 reduces HER2 (Erbb2)-induced
proliferation in cells that overexpress HER2. Wild type p53 promotes cell cycle arrest
and apoptosis, while mutant p53 promotes HER2-induced proliferation and cell cycle
progression in HER2 overexpressing cells (94). To determine whether p53 has a
regulatory role in cells containing normal physiological levels of Erbb2, mutant
(dominant negative) and wild type p53 should be introduced into cells with or without
Erbb2 and analyses quantifying DNA damage repair, survival, and proliferation should
be performed. In addition, the effect of modulating Erbb2 in cells with Trp53 mutations
should be investigated. In addition, we intend to perform double immunofluorescence
with p53 and PCNA to determine whether cells with p53 mutations are rapidly
proliferating.

Although our results are somewhat preliminary, the data presented herein suggest
that a strategy for administering an Erbb2 inhibitor to prevent UV induced skin
carcinogenesis might be effective if applied using a schedule that intermittently blocks
Erbb2 signaling. Currently, the only available preventative treatment for UV-induced
non-melanoma skin cancer is sunscreen which either absorbs, reflects or scatters UV rays
(reviewed in (95)). However, full protection for the entire UVA and UVB spectrum to
which we are exposed (290-400 nm) is not commercially available. Erbb2/HER2 is
activated in human and mouse skin 30 min after UV-irradiation as measured by phospho-
Erbb2 immunoreactivity (Figure 7). An improved preventative treatment would be
particularly beneficial for immunosuppressed patients that have an increased risk for UV-
related skin cancer.

Though the Erbb2 mutant model does not directly support the idea of Erbb2
inhibition as a skin cancer preventative, experiments using the Erbb2 inhibitor and Cre
recombinase virus-infected Erbb2\(^{\text{fl/fl}}\) keratinocytes do suggest that a short term inhibitor
of Erbb2 kinase function might be effective. The development of an effective Erbb2-
targeted inhibitor treatment would require the demonstration that prolonged loss of Erbb2
causes compensatory upregulation of Cdc25A and increased proliferation after UV-
exposure. The most likely treatment regime, supported by experiments using the Erbb2
inhibitor and Cre recombinase virus infection of Erbb2\(^{\text{fl/fl}}\) cells, would be one in which
Erbb2 is intermittently inhibited prior to UV-exposure to avoid prolonged Erbb2
inhibition and potential drug resistance. In addition, it will be important to confirm the
mechanism in which Erbb2 regulates the ATR pathway in response to UV-irradiation.
The targeting of a signaling protein downstream of Erbb2 might provide an effective
therapeutic option while reducing the risk of serious side effects (i.e. cardiotoxicity) and
drug resistance.

In order to further investigate the potential compensatory mechanism upon
prolonged Erbb2 loss, a number of additional analyses are indicated. First, to determine
whether the lack of an S-phase arrest is due to maintenance of Cdc25A, DNA content
flow cytometry should be analyzed in sham- and UV-irradiated, Cre recombinase virus-
infected cells in which Cdc25A levels have been increased by transfection with a
Cdc25A plasmid. If the maintenance of Cdc25A is responsible for the compensatory mechanism after genetic ablation of Erbb2, the increase of Cdc25A should repair the cell cycle defect in Cre infected cells. In addition, Cdc25A immunoreactivity should be analyzed in sham-irradiated, Cre recombinase virus-infected keratinocytes to determine the timeline in which Cdc25A is recovered after loss of Erbb2. A comparable \textit{in vivo} experiment would require the development of transgenic mice in which Cre recombinase expression targeted to the skin is conditionally expressed (i.e. tamoxifen-induced expression as described in (96)). This would allow us to observe the effects of UV-irradiation after short term loss of \textit{Erbb2} and determine the timeline in which a compensatory mechanism is developed. The ability to reduce Erbb2 in adult mice would also allow us to determine whether a compensatory mechanism occurs in during adulthood or only when Erbb2 is lost early in development when there is increased plasticity. These experiments will provide guidance for determining an appropriate treatment schedule for an Erbb2-targeted skin cancer preventative.

The mechanism through which Cdc25A is recovered after loss of Erbb2 should be investigated. If Erbb2 regulates maintenance of Cdc25A through the inhibition of Chk1 by the PI3K/Akt pathway (Figure 4), it is possible that other RTKs activate this pathway. EGFR, like Erbb2, is activated after UV-irradiation and has been demonstrated to promote UV-induced skin tumorigenesis (97). UV-irradiation induced activation of EGFR results in the activation of the PI3K/Akt pathway through heterodimerization with Erbb3 or association with adapter proteins (i.e. Gab1, Cbl (97-100)). Though the Erbb2-Erbb3 pathway is more potent (101), the EGFR-Erbb3 heterodimer is also able to activate this pathway. Erbb3 has six direct binding sites for the p85 subunit of PI3K, making it
the preferred Erbb receptor for initiating this signaling cascade (102-104). Since it has been suggested that incomplete inhibition of HER3 (Erbb3) in Herceptin-treated patients results in a cell’s ability to resist treatment (70;105), it is reasonable to consider that Erbb3 might be involved in the compensatory mechanism in Erbb2 mutant skin. However, preliminary data from an unrelated experiment suggests that there are not significant differences in EGFR and Erbb3 activation between sham-irradiated skin from Erbb2 mutant and littermate controls (in vivo, unpublished data). Therefore, other proteins capable of activating the PI3K/Akt pathway should be considered. 

Currently, a tumor experiment is underway to determine the influence of genetic ablation of Erbb2 on UV-induced skin carcinogenesis. The purpose of this experiment is to compare the time until tumor development, tumor multiplicity, incidence, volume, and stage in Erbb2 mutant mice and littermate controls following chronic UV-irradiation. Based on the results presented in this report, the improved DNA damage repair and decreased clonal expansion of cells with Trp53 mutations after UV-irradiation of Erbb2 mutant skin should translate to decreased mutagenesis and delayed skin tumor development compared to skin from littermate controls. The additional analyses proposed here would provide further insight into the potential outcome of this experiment.

The results presented in this report suggest that cells lacking Erbb2 recover Cdc25A, which may be responsible for the absence of an S-phase arrest after sham-and UV-irradiation in Erbb2 mutant skin when compared to the models using Cre recombinase viral infection, Erbb2 inhibition, and Erbb2-targeted siRNA transfection. A role for Erbb2 has also been implicated as a regulator of DNA repair mechanisms and
clonal expansion of cells with mutant p53. Because the improved DNA damage repair and increased mutagenesis cannot be attributed to an S-phase arrest, Erbb2 likely regulates these processes through mechanisms independent of its regulation of cell cycle progression.
Bibliography


(53) Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997 Apr 1;16(7):1647-55.


(95) Palm MD, O'Donoghue MN. Update on photoprotection. Dermatol Ther 2007 Sep;20(5):360-76.


